Published animal timeline
Key mouse experiments include an 11-day obesity model and a 28-day metabolic study. They observed body-composition and metabolic measures, but cannot predict human onset or outcomes.
Protocol / Research Dosing Guide
5-Amino-1MQ Dosage Guide: Oral vs. Injection, Reconstitution and Safety
An evidence-organized 5-Amino-1MQ research guide covering oral and subcutaneous community protocols, vial calculations, timing, half-life, safety, potential findings and regulatory status.
Last reviewed September 14, 202618 minute readResearch information only
Level 2 — Preclinical EvidenceNo published human trialsNot FDA approved
5-Amino-1MQ Quick Start
5-amino-1-methylquinolinium is a synthetic small molecule—not a true peptide—that inhibits nicotinamide N-methyltransferase (NNMT). Researchers study this pathway because NNMT participates in nicotinamide and methyl-donor metabolism, which may influence cellular NAD+ and SAM availability. Evidence remains laboratory and animal based.
Why researchers care
Fat-cell and metabolic signaling research
Class
Small-molecule NNMT inhibitor
Most common route
Oral in community reports
Cycle length
8–12 weeks reported; not validated
Regulatory status
Not FDA approved
Community discussions commonly cite 50–150 mg/day orally. Vial and subcutaneous framing also appears, but no human trial validates either route, amount, cycle, or clinical benefit.
Loading supplier information
5-Amino-1MQ Dosing Protocol and Schedule
No published human trial has established a safe or effective 5-Amino-1MQ dosage. The schedules below summarize preclinical research context and commonly reported community practices. They are not clinically validated human dosing recommendations.
Displayed example: 50 mg vial + 3 mL BAC water = 16.667 mg/mL, or approximately 166.67 mcg per U-100 unit.
| Phase | Community-reported amount | U-100 units | Volume |
|---|---|---|---|
| Days 1–2 tolerance reference | 2.5 mg once daily | 15 units | 0.15 mL |
| Days 3+ community reference | 5 mg once daily | 30 units | 0.30 mL |
| Split community example | 2.5 mg twice daily | 15 units each | 0.15 mL each |
Every row: Community Reported — No Validated Human Injectable Protocol
- 50 mg mathematically represents 10 draws at 5 mg
- 50 mg mathematically represents 20 draws at 2.5 mg
- Human subcutaneous bioavailability is unknown
- No validated oral-to-subcutaneous conversion exists
- Route-specific human safety has not been established
5-Amino-1MQ Supplies Needed
Planning duration
Neutral math based on the displayed 5 mg once-daily community schedule and 50 mg + 3 mL vial example—not a recommendation.
50 mg vials
2
U-100 syringes
14
BAC water
6 mL
Alcohol swabs
28
Sharps disposal
One compliant container
Modeled quantity
70 mg
5-Amino-1MQ Reconstitution Calculator
Vial-format concentration math
Concentration
16.667 mg/mL
Draw volume
0.15 mL
U-100 units
15
Mathematical draws per vial
20
This calculator applies only to vial-format concentration mathematics. It does not apply to oral capsules and does not recommend a dose.
Best Time to Take 5-Amino-1MQ: Morning or Night?
No human study has established an ideal time, food relationship, frequency, route timing, or missed-amount procedure. Rat half-life data cannot establish human timing.
Morning or evening?
Morning is more common in community reports. Reports of later-day sleep disruption are anecdotal, not controlled evidence.
With or without food?
No human study compares fed and fasted use. Food may alter oral absorption, while taking a capsule with food is only a community comfort convention.
Once daily or split timing?
Both appear in community reports. Split timing is partly rationalized from short rat PK, which does not prove a human benefit.
Oral versus subcutaneous timing?
The routes have different exposure patterns, but neither has a validated human timing schedule.
What if a scheduled amount is missed?
No established missed-dose directions exist. This page does not advise replacing, doubling, or rescheduling an amount.
5-Amino-1MQ Oral Capsules vs. Injection
| Factor | Oral capsules | Subcutaneous vial |
|---|---|---|
| Administration | Oral format | Reconstituted vial framing |
| Community-reported amounts | 50–150 mg/day | 2.5–5 mg/day |
| Frequency | Once daily or split | Usually discussed once daily |
| Absorption evidence | 38.4% in one rat study | Human subcutaneous PK unknown |
| Convenience | No mixing | Requires concentration math |
| Human evidence | Not established | Not established |
| Direct conversion | Not possible | Not possible |
Oral and injected quantities are not interchangeable. No validated conversion exists.
5-Amino-1MQ Half-Life and Dosing Frequency
The only numeric half-life and bioavailability values below come from an animal pharmacokinetic study.
IV half-life3.80 ± 1.10 hoursRat data
Rats; IV; Awosemo et al. 2021. It describes rat terminal elimination and cannot establish human timing.
Oral half-life6.90 ± 1.20 hoursRat data
Rats; oral; Awosemo et al. 2021. It describes rat terminal elimination and cannot establish human oral frequency.
Oral bioavailability38.4%Rat data
Rats; oral versus IV; Awosemo et al. 2021. It cannot predict human absorption.
Human oral half-lifeNot establishedNo published human PK
No human pharmacokinetic study was identified.
Human subcutaneous half-lifeNot establishedNo published human PK
Rodent subcutaneous exposure work exists, but no human half-life has been established.
5-Amino-1MQ Dosage Chart
| Route | Community-reported amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Oral | 50 mg once daily | Once daily | Community report | No |
| Oral | 100 mg once daily | Once daily | Community report | No |
| Oral | 150 mg once daily | Once daily | Community report | No |
| Oral | 50 mg morning + 50 mg midday | Split | Community report | No |
| Subcutaneous | 2.5 mg | Once daily | Community report | No |
| Subcutaneous | 5 mg | Once daily | Community report | No |
| Subcutaneous | 2.5 mg | Twice daily | Community report | No |
This chart reports community discussion ranges; it does not establish a clinical starting dose.
5-Amino-1MQ Reconstitution Guide
Concentration: 16.667 mg/mL
| Amount | Volume | U-100 units |
|---|---|---|
| 1 mg | approximately 0.06 mL | 6 units |
| 2.5 mg | 0.15 mL | 15 units |
| 5 mg | 0.3 mL | 30 units |
| 10 mg | 0.6 mL | 60 units |
- 1.Bring the vial to the appropriate preparation temperature.
- 2.Clean the vial stopper.
- 3.Draw the selected BAC-water volume.
- 4.Add the liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect the solution.
- 7.Label and refrigerate only when supported by validated product handling information.
- 8.Match the draw to the calculated concentration.
Reconstitution does not guarantee identity, quality, or sterility.
How 5-Amino-1MQ Works
5-Amino-1MQ
A membrane-permeable small molecule studied as an NNMT inhibitor.
5-Amino-1MQ Human Trials and FDA Status
Current status · verified September 14, 2026
No completed published human clinical trial or FDA-approved indication was identified.
- No established human dose
- No approved injectable formulation
- No established human pharmacokinetics
- Evidence is primarily preclinical
- Research-use labeling does not make a product an approved medication
A 2026 FDA warning letter named this substance in a facility-specific section 503B compounding compliance action. That letter is not a clinical safety finding or general approval decision.
Who Should Avoid 5-Amino-1MQ?
This is an evidence-gap list, not an established prescribing label or a list of proven contraindications.
Pregnancy and breastfeeding
No human safety data
Children and adolescents
No human safety data
Liver or kidney disease
Unknown; requires licensed clinical review
Cancer history
Theoretical concern; requires licensed clinical review
Cardiovascular disease or sleep disorders
Unknown; community reports cannot establish risk
Diabetes medications or other metabolism-affecting drugs
Theoretical interaction concern
Methyl-donor-sensitive therapies
Theoretical concern based on NNMT/SAM biology
Long-term use
No human safety data
5-Amino-1MQ Side Effects, Risks and Safety
Sleep disturbanceAnecdotal
Important limitation: Community reports; no controlled incidence data. Community reports are not controlled human safety evidence.
Warmth or increased resting heart rateAnecdotal
Important limitation: No controlled human safety evidence. Community reports are not controlled human safety evidence.
Oral stomach upsetAnecdotal
Important limitation: Frequency and amount relationship unknown. Community reports are not controlled human safety evidence.
Injection-site stinging or irritationAnecdotal
Important limitation: Route-specific human safety not established. Community reports are not controlled human safety evidence.
Liver or metabolic changesTheoretical / unknown
Important limitation: Animal metabolic findings do not define human harm. Community reports are not controlled human safety evidence.
Drug or supplement interactionsUnknown
Important limitation: No published human interaction studies. Community reports are not controlled human safety evidence.
Pregnancy and breastfeedingUnknown
Important limitation: No human developmental safety data. Community reports are not controlled human safety evidence.
Children and adolescentsUnknown
Important limitation: No pediatric research. Community reports are not controlled human safety evidence.
Long-term or repeated-cycle effectsUnknown
Important limitation: No human long-term follow-up. Community reports are not controlled human safety evidence.
5-Amino-1MQ Timeline and Monitoring
Community-observation timeline
Community cycles are often described as 8–12 weeks. Informal records may track weight/body composition, energy, sleep, resting heart rate, digestion, and laboratory markers.
Human clinical guidance
Not established. There is no validated human monitoring schedule, outcome timeline, stopping rule, or laboratory panel.
5-Amino-1MQ Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Fat-mass changes | Level 2 — preclinical | Mouse studies reported changes in fat-mass or weight-gain measures | Animal findings do not establish human fat loss |
| NAD+ changes | Level 2 — preclinical | Cell and animal research connects NNMT inhibition with nicotinamide-related metabolic pathways | Human magnitude and benefit are unknown |
| Appetite reduction | Level 2 — preclinical | Appetite suppression was not the apparent mechanism in reported mouse findings | This does not establish human appetite effects |
| Human weight loss | Not established | No published controlled human result | Community claims cannot establish efficacy |
| Energy changes | Not established | No controlled human finding | Anecdotes do not establish direction or frequency |
5-Amino-1MQ Storage and Handling
Oral capsules
No independently verified formulation-specific shelf life was identified. Follow the actual labeled product conditions; generic room-temperature limits are not validated here.
Unreconstituted vial
No compound-specific stability study was identified for the displayed lyophilized formulation. Cold, dark storage claims remain supplier conventions unless supported by product data.
Reconstituted vial
No independently verified 5-Amino-1MQ stability duration was identified. A 2–4 week claim is a supplier or community handling convention—not validated stability data.
Appearance after preparation
Do not treat a cloudy, discolored, or particle-containing solution as normal. Appearance cannot confirm identity or sterility.
5-Amino-1MQ Troubleshooting
Solution looks cloudy or contains particles
Stop. Do not treat the solution as usable; contact the dispensing professional or qualified supplier. Appearance cannot confirm sterility.
Target amount produces an impractically large draw
Recheck vial quantity, added volume, target units, and the vial label. The calculator reports math only and should not be used to redesign an amount.
Oral and subcutaneous quantities appear inconsistent
They represent different routes with no validated conversion and must not be compared as equivalent exposures.
Resting heart rate changes
This page cannot diagnose the cause. Stop relying on community guidance and seek licensed clinical review.
Sleep disruption
Timing effects are not established. A new or concerning symptom requires licensed clinical review.
Stomach upset
Oral stomach upset is anecdotal; severity or persistence requires clinical review.
A scheduled amount was missed
No validated missed-dose procedure exists; do not infer that doubling is safe.
Calculator result does not match the vial label
Confirm that mg, mL, target amount, and U-100 scale were entered correctly. The physical label takes priority over assumptions.
Selected amount exceeds total vial quantity
The input is mathematically impossible for one vial; correct the entry rather than treating it as a usable result.
5-Amino-1MQ vs. AOD-9604 vs. Semaglutide vs. NAD+
| Compound | Mechanism | Common research or approved route | Appetite pathway | Evidence level | FDA status | Human evidence | Main limitation |
|---|---|---|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition | Oral community reports; research vial framing | Not established | Level 2 | Not approved | No published trials | Human dose, safety, and benefit unknown |
| AOD-9604 | Modified hGH fragment research | Investigational routes | Not a GLP-1 appetite agonist | Preclinical / limited human | Not approved | Limited human research | No approved weight-loss indication |
| Semaglutide | GLP-1 receptor agonist | Approved subcutaneous and oral products | Yes | Level 5 for approved uses | Approved for specific indications | Extensive controlled trials | Not interchangeable with research compounds |
| NAD+ | Metabolic cofactor | Clinical and research routes vary | No direct appetite-drug mechanism | Context dependent | Not approved as a weight-loss drug | Human biology established; protocol claims vary | Route and indication claims require specific evidence |
Evidence levels describe different evidence bases, not winners. This comparison does not recommend combining these compounds.
5-Amino-1MQ Frequently Asked Questions
What is 5-Amino-1MQ?
It is 5-amino-1-methylquinolinium, a synthetic small molecule studied as an NNMT inhibitor.
Is it actually a peptide?
No. It is a small molecule commonly marketed beside research peptides.
What is NNMT?
Nicotinamide N-methyltransferase is an enzyme that methylates nicotinamide using SAM and produces 1-MNA.
Why is NNMT researched?
It links nicotinamide and methyl-donor metabolism with metabolic signaling in cells and animal models.
Is 5-Amino-1MQ FDA approved?
No FDA-approved indication or formulation was identified.
Are there published human trials?
No completed published human clinical trial was identified as of the review date.
What oral quantities appear in community reports?
Community discussions commonly mention 50–150 mg/day; these are not validated human doses.
What subcutaneous quantities appear in community reports?
Community discussions commonly mention 2.5–5 mg; no human injectable protocol validates them.
Are oral and injectable quantities interchangeable?
No. No validated conversion exists.
What is known about oral bioavailability?
One rat study reported 38.4%; human bioavailability is unknown.
What is known about human half-life?
No published human oral or subcutaneous half-life has been established.
What is known about timing?
Morning and split timing are community practices, not controlled human findings.
How is a 10 mg vial calculated?
With 1 mL, concentration is 10 mg/mL; 1 mg is 0.10 mL or 10 U-100 units.
How is a 20 mg vial calculated?
With 2 mL, concentration is 10 mg/mL; 2.5 mg is 0.25 mL or 25 U-100 units.
How is a 50 mg vial calculated?
With 3 mL, concentration is about 16.667 mg/mL; 2.5 mg is 0.15 mL or 15 U-100 units.
What does one U-100 unit equal?
One unit is 0.01 mL. Its mass depends on the vial concentration; at 50 mg in 3 mL it contains about 0.1667 mg.
What cycle and rest periods are community reported?
Eight to twelve weeks followed by four to six weeks appears in community reports; neither interval is clinically validated.
What side effects are established?
No controlled human incidence data exist. Reported effects remain anecdotal or theoretical.
What long-term safety information exists?
No published human long-term or repeated-cycle safety evidence was identified.
How should conflicting claims be interpreted?
Prioritize primary studies and official records, separate animal from human evidence, and treat unsourced community claims as unvalidated.
Sources and Research
Mechanism and animal evidence
2018 print issue; published online 2017
1. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Biochemical Pharmacology.
- Study type
- Cell and animal experiment
- Species or population
- 3T3-L1 adipocytes and diet-induced-obese mice
- Route
- Laboratory exposure and subcutaneous animal administration
- Relevant finding
- A membrane-permeable NNMT inhibitor reduced 1-MNA in adipocytes and changed obesity-related measures in mice.
- Limitation
- Preclinical work cannot establish a human dose, benefit, timing, or safety profile.
- DOI
- 10.1016/j.bcp.2017.11.007
- PMID
- 29155147
Pharmacokinetics
2021
2. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. Journal of Pharmaceutical and Biomedical Analysis.
- Study type
- Bioanalytical validation with rat pharmacokinetic study
- Species or population
- Rats
- Route
- Intravenous and oral
- Relevant finding
- Reported terminal half-lives of 3.80 ± 1.10 hours IV and 6.90 ± 1.20 hours oral, with 38.4% oral bioavailability.
- Limitation
- A single rat PK experiment cannot establish human oral or subcutaneous pharmacokinetics or timing.
- DOI
- 10.1016/j.jpba.2021.114255
- PMID
- 34304009
Animal evidence
2024
3. Nicotinamide N-methyltransferase Inhibition Mitigates Obesity-Related Metabolic Dysfunctions
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Diabetes, Obesity and Metabolism.
- Study type
- Controlled animal experiment with pharmacokinetic and tissue-distribution work
- Species or population
- Diet-induced-obese mice
- Route
- Once-daily experimental administration; separate IV, oral, and subcutaneous PK cohorts
- Relevant finding
- The 28-day experiment reported dose-related effects on weight/fat-mass gain and metabolic measures, with tissue exposure after subcutaneous administration.
- Limitation
- Mouse outcomes and exposure do not establish human weight loss, dosing, safety, or a human subcutaneous half-life.
- DOI
- 10.1111/dom.15879
- PMID
- 39161060
Regulatory status
2026
4. GenoGenix LLC — FDA Warning Letter 718739
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. FDA Warning Letters.
- Study type
- Official regulatory correspondence
- Species or population
- Not applicable
- Route
- Not applicable
- Relevant finding
- The letter names 5-amino-1-methylquinolinium iodide among bulk substances not eligible for the facility's section 503B compounding activity.
- Limitation
- This is a facility-specific compliance action, not a clinical safety trial or a general approval decision.
- DOI
- Not applicable
- PMID
- Not applicable